To avoid nonspecific off-target effects of 6-AN, we manipulated the PPP activity by overexpressing or knocking down its rate-limiting enzyme G6PD in the PTEN null prostate cancer PC3 cells. This evidence concerns the gene G6PD and prostate carcinoma.